Company
Mylan Ireland LTD
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
3
Approvals since 2021
2
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Arixtra new use Dec 23, 2024
- Pretomanid new use OrphanNov 22, 2024
- Pretomanid approved NovelPriority reviewOrphanAug 14, 2019
- Yupelri approved NovelNov 9, 2018
- Arixtra new use May 26, 2005
- Arixtra new use May 28, 2004
- Arixtra new use May 28, 2004
- Arixtra new use Priority reviewJun 17, 2003
- Arixtra approved NovelPriority reviewDec 7, 2001
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
- Arixtra Fondaparinux Sodium · 2001
- Pretomanid Pretomanid · 2019
- Yupelri Revefenacin · 2018
- Miacalcin Calcitonin Salmon · 1986
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.